Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. - Wikidata - awgldk - TriplyDB

Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study.

Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study.

http://www.wikidata.org/entity/Q37130166

about

Targeting platelet-derived soluble CD40 ligand: a new treatment strategy for HIV-associated neuroinflammation?Diagnosing and managing diabetes in HIV-infected patients: current concepts HIV and aging: emerging research issues Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.Developments in HIV-1 immunotherapy and therapeutic vaccination.Platelet interactions with viruses and parasites.Characterization of platelet-monocyte complexes in HIV-1-infected individuals: possible role in HIV-associated neuroinflammation.Systemic effects of inflammation on health during chronic HIV infection Coagulation and morbidity in treated HIV infection.A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy.Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?Residual immune dysregulation syndrome in treated HIV infection.Chronic HIV disease and activation of the coagulation system The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial Aspirin Use for Primary and Secondary Prevention in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Patients.Thromboelastography on plasma reveals delayed clot formation and accelerated clot lyses in HIV-1 infected persons compared with healthy controls Novel Antiplatelet Activity of Minocycline Involves Inhibition of MLK3-p38 Mitogen Activated Protein Kinase Axis.Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.Silymarin suppresses basal and stimulus-induced activation, exhaustion, differentiation, and inflammatory markers in primary human immune cells Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial.Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+ T-Cell Activation.Immune activation and cardiovascular disease in chronic HIV infection.Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis.Cancer prevention in HIV-infected populations.Inflammation, immune activation, and cardiovascular disease in HIV.Serious Non-AIDS events: Immunopathogenesis and interventional strategies.The Aspirin Foundation Scientific Conference: the history, the present state and the future of aspirin prophylaxis.Cardiovascular disease and HIV infection.Dendritic cell dysregulation during HIV-1 infection.HIV and the heart: the impact of antiretroviral therapy: a global perspective.Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing.Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND)Risk of coronary heart disease in patients with HIV infection.Epidemiology of ischemic heart disease in HIV.Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection Strategies to limit immune-activation in HIV patients.Coronary Artery Disease in HIV-Infected Patients: Downside of Living Longer.Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332.Platelet activation suppresses HIV-1 infection of T cells.

P2860

Q27010594-EB39D806-9043-4105-B14D-61DFCB598E35 Q27014697-3C345F3E-ED64-40FB-BADA-1753644C0F01 Q27016011-B83DEAFC-59B1-446F-B81C-2B2A268B53A9 Q27024262-72517D5C-23F2-4490-A802-5361F6ED598A Q30248286-1C1EBC9A-7D68-46B9-8C29-BE66FE3D37C0 Q30364312-F470A487-E98A-40FD-8F59-627B5C825D03 Q33422357-10867547-D793-4679-8E76-5191E3C2A79B Q33573879-38AB0CDF-D303-4B50-BD97-962006D764EE Q33577551-1FA28D5C-834E-42A9-9907-185025997EDA Q33614424-CC3D2409-1F46-4A93-840C-ED0350DF8FF1 Q33629231-689E2634-54DE-4B85-BFD4-F5E56AAB9509 Q33649200-794EB2B3-2695-41EF-BE35-246B37EB89AE Q34020121-7389F4D2-22DA-459F-8B21-222292669E55 Q34342368-E2D84DCE-FF82-4D4E-804F-53DB84E49837 Q34818798-4865BF7B-A6C9-4291-8CDB-416A93C46B0F Q35072103-4EAAA7AD-8C0B-47EE-A24E-21DF5D26CC79 Q35785698-E5917421-51F6-416B-8451-0DE0819E84F0 Q36043123-2C7633C3-A7D8-4981-88F3-67E410CA7527 Q36244001-C8EE5613-E89E-4D60-B58F-1FA6A4B7CFE7 Q36269639-149820C9-099B-4A82-97E5-800D6ED0E9C4 Q36360872-B0A7041F-B69F-4F36-97DD-CA7A600924A9 Q36487836-50FD5621-7046-4E5C-8A31-58D814EE2F2B Q36556082-8F34B0A9-6C73-4871-B609-2D10D2D947F4 Q36668917-3078AA25-372D-4274-84DE-97D853E39006 Q36680086-D529BA19-EA9B-4CA3-A1CF-39319C91F41D Q36957752-392017B9-F825-4C60-8475-D0EE6EFFB306 Q37418140-70D0FA59-71A6-403A-BE47-C0BA849798E2 Q37528500-354785F8-E53A-428C-B92D-9CF03B18CFDC Q37661603-D7FD4B5C-BAD1-4980-85F5-1A4B785B0166 Q38114911-5AEF0406-58F0-4438-89BB-9564DD120FF0 Q38152708-222B2B1C-6FF4-4B70-9B05-3AD057737531 Q38177684-D58CA572-4ECF-404A-B916-5F5BADC91884 Q38258410-6285011F-3EC3-46F2-88AA-9E21A6944061 Q38261508-F76E4CE7-FE6E-41E3-B0D7-BED10AF2A6B1 Q38629009-8B72A927-4233-41DB-BA12-9BE90B4D271B Q38749963-30E07732-1A1A-444F-80B3-32C08764323F Q38985926-5F3AC6A1-8057-4F4D-9FA0-962D93B3D3AB Q39165028-35801B8B-8840-44E1-A50C-F6804FE60CD9 Q40662634-308A3906-3EF0-4901-90CD-D29394BCEB77 Q40897514-82707607-8A97-40A3-882F-65BB209A6359

P2860

Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study.

http://www.wikidata.org/entity/Q37130166

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Aspirin attenuates platelet ac ...... oviral therapy: a pilot study.

@en

Aspirin attenuates platelet ac ...... oviral therapy: a pilot study.

@nl

type

label

Aspirin attenuates platelet ac ...... oviral therapy: a pilot study.

@en

Aspirin attenuates platelet ac ...... oviral therapy: a pilot study.

@nl

prefLabel

Aspirin attenuates platelet ac ...... oviral therapy: a pilot study.

@en

Aspirin attenuates platelet ac ...... oviral therapy: a pilot study.

@nl

P1433

Q37130166-E7D38A41-B512-4517-BB5C-FA4315662F69

P1476

Q37130166-A76B57BA-BF6E-4271-B979-DC45443D665D

P2093

Q37130166-046BE568-C8CB-45B6-9DE9-F257CA3E65A6

Q37130166-069E1B81-CBB2-4719-8680-6B6431943D6E

Q37130166-0854B164-ECB7-4342-812F-2B50511311A6

Q37130166-198CF3FC-13FE-47F7-A30B-3B8EF356C2BF

Q37130166-22B541CE-552A-415E-8C3A-6C5E7FCCC6DB

Q37130166-6685DC34-8E45-4B8A-AEB1-6555250E8E2F

Q37130166-8C1CCF1A-CF0B-4A5F-92F9-644D521602B4

Q37130166-A2214C5C-D04C-44D2-A8C5-840701330713

Q37130166-AEBDBAF9-B25F-48EA-9104-1B0F0EDF8344

Q37130166-F1BADE31-7610-46DE-A885-24CD142F55CD

P2860

Q37130166-055DC9DF-0127-40D6-89F5-29E852E50C09

Q37130166-12C8F4C8-7A4F-4829-8ECC-A0E696DF927C

Q37130166-271BD870-EB64-41D0-8262-D545758825A5

Q37130166-3D41A185-AD68-44B8-B1F3-778C38A88DAC

Q37130166-45996E8D-2B89-4B9D-B9A4-947D74D34077

Q37130166-460F08B0-4450-4518-8188-D75D59AF3E08

Q37130166-48CDF434-DAB8-4EE3-85DE-254A2FDFA5C4

Q37130166-4AFBDE59-DD85-4806-A154-A01EE6C07FFA

Q37130166-4C76AEC1-1DB4-402B-8539-A342B0C35BAC

Q37130166-4D998460-ED26-4FCF-892E-BBEE9021F7D5

P304

Q37130166-12B6A8F1-6386-4EC8-885B-5D81EAFC1A4C

P31

Q37130166-B46D7297-EC82-4B5F-838C-FA9D3736FBEE

P356

Q37130166-17F29611-9401-4731-8FB2-71B676F68C5E

P407

Q37130166-6DA8BA74-EF6C-4A88-9E87-8810AEF0BA13

P433

Q37130166-ED66F974-661D-4215-AA82-82E4CFF50FBF

P478

Q37130166-E730BCEA-3F34-4D73-8E4B-A436C13F91DE

P577

Q37130166-94037181-AE95-4158-9A69-174BF565C0C2

P698

Q37130166-25802092-0B8B-413B-8E20-46F590D1D2EA

P921

Q37130166-506FEFD5-0699-4893-9732-52D56CD22FE3

Q37130166-95301BD4-E66F-4DC4-9D80-E7AB5DF09DA6

Q37130166-B52AD2E9-8F04-4F8B-99F3-84C6743C92FC

P932

Q37130166-B9ACE7E4-FB7B-4F35-8D5B-D473FDB52F19

P356

QAI.0B013E31828A292C

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Aspirin attenuates platelet ac ...... oviral therapy: a pilot study.

@en

P2093

Emilie Montenont

http://www.w3.org/2001/XMLSchema#string

Gabrielle Gettenberg

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Berger

http://www.w3.org/2001/XMLSchema#string

Judith A Aberg

http://www.w3.org/2001/XMLSchema#string

Karen Cavanagh

http://www.w3.org/2001/XMLSchema#string

Liang Hu

http://www.w3.org/2001/XMLSchema#string

Meagan O'Brien

http://www.w3.org/2001/XMLSchema#string

Michael A Nardi

http://www.w3.org/2001/XMLSchema#string

Michael Merolla

http://www.w3.org/2001/XMLSchema#string

Nina Bhardwaj

http://www.w3.org/2001/XMLSchema#string

P2860

Aspirin down-regulates tryptophan degradation in stimulated human peripheral blood mononuclear cells in vitro

Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses

Association of low level viremia with inflammation and mortality in HIV-infected adults

Inhibition of NF-kappa B by sodium salicylate and aspirin

CD4+ count-guided interruption of antiretroviral treatment

Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis.

Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.

Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.

Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV.

HIV-induced T-cell activation/exhaustion in rectal mucosa is controlled only partially by antiretroviral treatment

P304

280-288

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0B013E31828A292C

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23406976

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3756489

http://www.w3.org/2001/XMLSchema#string